GLP-1 receptor agonist
8 sourced research updates tagged GLP-1 receptor agonist, newest first — what changed, what the evidence shows and what it means for how people run a protocol.
Taking metformin and a GLP-1 together: what actually changes
Metformin and GLP-1 receptor agonists are routinely prescribed together and there is no pharmacokinetic interaction requiring a dose change between them.
Retatrutide's Phase 3 results are in — and the filing slipped to 2027
Eli Lilly reported in July 2026 that retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, met its primary endpoints in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, with weight loss of roughly…
The first small-molecule GLP-1 pill is approved — what Foundayo changes
In April 2026 the FDA approved orforglipron (brand name Foundayo), the first small-molecule oral GLP-1 receptor agonist for chronic weight management.
The muscle problem with GLP-1s finally has trial data behind it
Up to 40% of the weight lost on GLP-1 therapy can come from lean mass, not fat. Two Phase 2 programs now show that this is partly fixable with drugs: the BELIEVE trial combined semaglutide with…
Is there a best time of day to take a weekly GLP-1?
Once-weekly semaglutide and tirzepatide can be injected at any time of day, with or without food, because their half-lives are measured in days rather than hours.
You missed your weekly GLP-1 dose — what the label actually says
For once-weekly semaglutide, the label says take the missed dose within 5 days of the scheduled day; past that, skip it and resume your normal schedule.
When will orforglipron actually be available to fill at a pharmacy?
Orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist that has completed its Phase 3 ATTAIN and ACHIEVE programs and is under regulatory review.
How much bacteriostatic water for a 10 mg retatrutide vial
Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg per mL, so one unit on a U-100 insulin syringe holds 50 mcg and a 1 mg dose is 20 units.